The few only other published studies which talk of direct involvement of ESCRT family members in cancer resistance mechanisms involve CHMP2A, which affects the sensitivity of cancer cells to natural killer-cell-mediated cytotoxicity in glioblastoma and head and neck squamous cell carcinoma which might participate in the development of drug resistance [17]. This evidence concerns the gene CHMP2A and glioblastoma.